Holter Device for Fetal Monitoring
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new method to monitor a baby's heart activity before birth. Researchers aim to determine if a Holter device, a portable ECG device typically used to check heart activity over time, can also work for unborn babies. They will compare this method with the standard Doppler Fetal Heart Rate device. Pregnant women carrying one or two babies from 32 weeks to full term, who have undergone routine testing, might be suitable for this trial. As an unphased trial, this study offers participants the chance to contribute to pioneering research that could enhance prenatal care.
Do I need to stop my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications.
What prior data suggests that this Holter device is safe for fetal monitoring?
Research has shown that the Holter monitor is generally safe for people. This device commonly tracks heart activity over time without major risks. Some individuals might experience slight discomfort or skin irritation where the sensors attach, but these issues are usually minor. The Holter monitor is noninvasive, meaning it doesn't involve surgery or entering the body, making it a safe choice for monitoring heart activity, even in pregnant women. The aim is to determine if it can also effectively capture the baby's heart signals.12345
Why are researchers excited about this trial?
Researchers are excited about the Holter device for fetal monitoring because it offers a non-invasive, continuous way to track fetal heart activity from 32 weeks of pregnancy until full term. Unlike traditional methods such as intermittent ultrasound or Doppler devices, which provide snapshots of fetal health at specific times, the Holter device continuously records data, giving a more comprehensive view of fetal well-being. This real-time monitoring can potentially help in detecting issues earlier and managing complications more effectively, leading to better outcomes for both mother and baby.
What evidence suggests that this Holter device is effective for fetal monitoring?
Studies have shown that the Holter device, used by participants in this trial, can effectively track a baby's heartbeat for extended periods without causing discomfort to the mother. Unlike the traditional Doppler method, which can sometimes be confusing or uncomfortable, the Holter device offers continuous and clear monitoring, making it especially useful for observing the baby's health. Research also suggests that this device may help detect issues like fetal tachycardias, unusually fast heartbeats that can lead to serious problems if not monitored. Overall, these findings indicate that the Holter device is a promising tool for safe and effective baby monitoring.25678
Who Is on the Research Team?
Martin Frasch, MD, PhD
Principal Investigator
University of Washington
Are You a Good Fit for This Trial?
This clinical trial is open to pregnant women carrying one or two babies, who are between 32 weeks gestation and full term. They should be after their routine antepartum testing with no specific exclusions mentioned.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Data Collection
Holter ECG device and Doppler FHR device are attached to pregnant women to capture fetal cardiac activity
Follow-up
Participants are monitored for safety and effectiveness after data collection
What Are the Treatments Tested in This Trial?
Interventions
- Holter Device
Holter Device is already approved in United States, European Union, Canada for the following indications:
- Cardiac arrhythmias
- Fainting spells
- Palpitations
- Monitoring after myocardial infarction
- Cardiac arrhythmias
- Fainting spells
- Palpitations
- Monitoring after myocardial infarction
- Cardiac arrhythmias
- Fainting spells
- Palpitations
- Monitoring after myocardial infarction
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Washington
Lead Sponsor
Duke University
Collaborator